Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688771 | 0.85 | POLB (0.43) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32688834 | 0.82 | POLB (0.44) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17777227 | 0.79 | POLB (0.48) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32689067 | 0.78 | POLB (0.45) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32689000 | 0.78 | NPC1 (0.43) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32689150 | 0.78 | HPGD (0.48) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32689213 | 0.78 | POLB (0.45) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32688820 | 0.77 | POLB (0.44) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2065143 | 0.76 | POLB (0.46) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL32689244 | 0.76 | POLB (0.50) | POLBNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115400-A1 | METHOD FOR PRODUCING SILICON COMPOUND, AND SILICON COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-04-16 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1877377-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | Wyeth (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118955-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | WYETH (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
| US-4128509-A | FRAGRANCE | MONSANTO COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | TPMT, TH, HTR3C | POLB 2192/4885NPC1 4132/4885RAB9A 2231/4885 |
| US-20200115400-A1 | METHOD FOR PRODUCING SILICON COMPOUND, AND SILICON COMPOUND | SI, SIK1, CA1 | POLB 773/4885NPC1 3325/4885RAB9A 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.